The Week in Diabetes and Endocrinology -- April 3, 2026

The Week in Diabetes and Endocrinology -- April 3, 2026

From Hormone Insight by FWA

April 5, 2026 · 24 min

About this episode

This episode covers six important stories in diabetes and endocrinology for the week of April 3, 2026.

The Week in Diabetes & Endocrinology — Episode 001 | April 3, 2026 From Hormone Insight (hormoneinsight.com) Six stories this week that endocrinologists, diabetologists, and internists need to know. TIMESTAMPS: 0:00 — Introduction & This Week's Stories 1:30 — Orforglipron (Foundayo) FDA Approval: The Oral GLP-1 Pill — Access-Changer, Not Game-Changer 7:00 — Semaglutide 7.2 mg (Wegovy HD): 21% Weight Loss, But Watch the Dysesthesia Signal 11:30 — Insulin Icodec (Awiqli): Once-Weekly Insulin — Sounds Great Until You Think About Sick Days 16:00 — SURPASS-CVOT Post-Hoc in JAMA Cardiology: Tirzepatide's Cardiorenal NNT of 27 19:30 — AACE 2026 Type 2 Diabetes Algorithm Update 21:30 — GLP-1 RAs in Parkinson's Disease: 5 RCTs, 708 Patients, No Signal 24:00 — Closing Thoughts REFERENCES & SHOW NOTES: ▸ Orforglipron FDA approval: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 ▸ Wegovy HD FDA approval: https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide ▸ Awiqli FDA approval…

Topics covered

  • Diabetes
  • Endocrinology
  • FDA Approvals
  • Weight Loss Medications
  • Insulin Treatments
  • Clinical Trials

Keywords

  • Diabetes
  • Endocrinology
  • FDA Approval
  • Weight Loss
  • Insulin
  • Clinical Trials
  • GLP-1

Mentioned in this episode

Organizations: Hormone Insight, AACE

Products: Orforglipron, Semaglutide, Insulin Icodec, Tirzepatide

More episodes of Hormone Insight

Explore listener stats, chart rankings, contacts and more on the Hormone Insight podcast page.